ALB and adenocarcinoma: For OS, according to univariate analyses, lower OS was significantly associated with non-adenocarcinoma and non-squamous histology (HR = 3.70, 95%CI 1.07–12.74, p = 0.038), the presence of symptomatic CNS metastases (HR = 3.61, 95% CI 1.64–7.94, p = 0.001), with CS administrated at the time of the first cycle of nivolumab (HR = 2.54, 95% CI 1.21–5.32, p = 0.014), with PS 2 (HR = 2.42, 95% CI 1.32–4.47, p = 0.005) and Albumine level at 1st cycle of nivolumab <30g/l (HR = 2.54, 95% CI 1.38–4.69, p = 0.003) (Table 5).